Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Normal-appearing white matter in multiple sclerosis is in a subtle balance between inflammation and neuroprotection.
Altered likelihood of brain activation in attention and working memory networks in patients with multiple sclerosis: An ALE meta-analysis.
Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes.
Peripheral and Central Nervous System Drugs Advisory Committee Meeting: Alemtuzumab (BLA 103948\5139) Background Package
Benefit of Endermology on Indurations and Panniculitis/Lipoatrophy During Relapsing-Remitting Multiple Sclerosis Long-Term Treatment with Glatiramer Acetate.
Rescue Therapy Using Rituximab for Multiple Sclerosis.
Sanofi withdraws Campath in US and EU
Effects of rituximab on lymphocytes in multiple sclerosis and neuromyelitis optica.
A complex role of herpes viruses in the disease process of multiple sclerosis.
[The Sjögren's syndrome and multiple sclerosis: similarity and differences.]
Lesion morphology at 7 Tesla MRI differentiates Susac syndrome from multiple sclerosis.
Significant Percentage of MS Patients Receiving Alemtuzumab in Genzyme’s Phase 2 Trial Remain Free of Clinically Active Disease
Rare variants in the CYP27B1 gene are associated with multiple sclerosis.
Receptos Reports Positive Phase 2 Results for TOUCHSTONE Trial of RPC1063 in Ulcerative Colitis
Takeda Submits a New Drug Application for Glatiramer Acetate in Japan for the Relapse Prevention of Multiple Sclerosis
Copolymer 1 inhibits manifestations of graft rejection.
Antiviral drug ganciclovir is a potent inhibitor of microglial proliferation and neuroinflammation.
Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota.
SIRT1 deacetylates RORγt and enhances Th17 cell generation.
Single-use autoinjector for peginterferon-β1a treatment of relapsing-remitting multiple sclerosis: safety, tolerability and patient evaluation data from the Phase IIIb ATTAIN study.
Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial.
GeNeuro and Servier sign partnership to develop first medicine addressing a causal factor of multiple sclerosis
Role of the Blood-Brain Barrier in Multiple Sclerosis.
Fine-Mapping the Genetic Association of the Major Histocompatibility Complex in Multiple Sclerosis: HLA and Non-HLA Effects.
Active Biotech's partner Teva initiates a further clinical trial in multiple sclerosis

Pages